Weekly docetaxel and bortezomib in the treatment of patients with advanced hormone refractory prostate cancer (HRPC): A Minnie Pearl Cancer Research Network phase II trial.

被引：0
|
作者：
Meluch, AA
Spigel, DS
Greco, FA
Barton, JH
Messina, G
Gould, B
Rovito, MA
Hainsworth, JD
机构：
[1] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA
[2] Wellstar Hlth Syst Canc Res, Marietta, GA USA
[3] Consultants Med Oncol & Hematol, Drexel Hill, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：436S / 436S
页数：1
相关论文
共 50 条
  • [21] Weekly docetaxel for advanced hormone-refractory prostate cancer
    Pepe, A.
    Usset, A.
    Calabria, C.
    Savio, G.
    Palmisano, V.
    Leonardi, V.
    Laudani, A.
    Arcuri, C.
    Giresi, A.
    Agostara, B.
    ANNALS OF ONCOLOGY, 2006, 17 : VII154 - VII154
  • [22] A phase I study of estramustine, weekly docetaxel and carboplatin (EDC) chemotherapy in patients with hormone refractory prostate cancer (HRPC).
    Oh, WK
    Hagmann, E
    Manola, J
    George, DJ
    Gilligan, TD
    Smith, MR
    Kaufman, DS
    Kantoff, PW
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 420S - 420S
  • [23] Weekly docetaxel and epirubicin in treatment of advanced hormone-refractory prostate cancer
    Petrioli, Roberto
    Paolelli, Loretta
    Francini, Edoardo
    Manganelli, Antonio
    Salvestrini, Francesco
    Francini, Guido
    UROLOGY, 2007, 69 (01) : 142 - 146
  • [24] Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC)
    Kattan, Joseph G.
    Farhat, Fady S.
    Chahine, Georges Y.
    Nasr, Fady L.
    Moukadem, Walid T.
    Younes, Fariha C.
    Yazbeck, Nadine J.
    Ghosn, Marwan G.
    INVESTIGATIONAL NEW DRUGS, 2008, 26 (01) : 75 - 79
  • [25] Bevacizumab, erlotinib, and imatinib in the treatment of patients (pts) with advanced renal cell carcinoma (RCC): A Minnie Pearl Cancer Research Network phase I/II trial.
    Hainsworth, JD
    Sosman, JA
    Spigel, DR
    Patton, JF
    Thompson, DS
    Sutton, V
    Hart, LL
    Yost, K
    Greco, FA
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 388S - 388S
  • [26] First line treatment with weekly docetaxel, vinorelbine, and trastuzumab in HER2 overexpressing metastatic breast cancer (HER2+MBC): A Minnie Pearl Cancer Research Network phase II trial.
    Yardley, DA
    Greco, FA
    Porter, LL
    Burris, HA
    Phelps, C
    Webb, C
    Schlabach, L
    Fichtel, LM
    Hainsworth, JD
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 37S - 37S
  • [27] Paclitaxel and mitoxantrone in the treatment of metastatic breast cancer: A phase II trial of the Minnie Pearl Cancer Research Network
    Hainsworth, JD
    Calvert, S
    Greco, FA
    CANCER INVESTIGATION, 2002, 20 (7-8) : 863 - 871
  • [28] Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma - Phase II trials of the Minnie Pearl Cancer Research Network
    Hainsworth, JD
    Burris, HA
    Billings, FT
    Bradof, JE
    Baker, M
    Greco, FA
    CANCER, 2001, 92 (09) : 2391 - 2398
  • [29] A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer
    Goodin, S
    Rao, KV
    Kane, M
    Dave, N
    Capanna, T
    Doyle-Lindrud, S
    Engle, E
    Jin, LX
    Todd, M
    DiPaola, RS
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 56 (02) : 199 - 204
  • [30] A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer
    Susan Goodin
    Kamakshi V. Rao
    Michael Kane
    Nisha Dave
    Terry Capanna
    Susan Doyle-Lindrud
    Elizabeth Engle
    Lixian Jin
    Mary Todd
    Robert S. DiPaola
    Cancer Chemotherapy and Pharmacology, 2005, 56 : 199 - 204
12345